Post Chemotherapy RPLND in Patients with Elevated Markers

Current Concepts and Clinical Outcome

Stephen D W Beck, Richard Foster, Richard Bihrle, Lawrence Einhorn, John P. Donohue

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Elevated serum tumor markers after cisplatin-based chemotherapy usually contraindicate surgery because of the presence of active germ-cell elements; however, some patients have undergone PCRPLND with curative intent. We evaluated the role of surgery to resect retroperitoneal-only marker positive tumor. Residual germ-cell cancer was identified in 50% of patients with elevated tumor markers with one third alive at 5 years; 5-year survival with residual teratoma or necrosis was 77.5% and 85.7%, respectively. Predictors of retroperitoneal teratoma or fibrosis included declining tumor makers at surgery, βHCG < 100, and first-line chemotherapy. Predictors of death included rising preoperative βHCG, elevated AFP, redo RPLND, and active germ-cell cancer in the resected specimen. Select patients with elevated tumor markers after chemotherapy are cured with surgery.

Original languageEnglish
Pages (from-to)219-225
Number of pages7
JournalUrologic Clinics of North America
Volume34
Issue number2
DOIs
StatePublished - May 2007

Fingerprint

Tumor Biomarkers
Drug Therapy
Germ Cell and Embryonal Neoplasms
Teratoma
Residual Neoplasm
Germ Cells
Cisplatin
Fibrosis
Necrosis
Biomarkers
Survival
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Post Chemotherapy RPLND in Patients with Elevated Markers : Current Concepts and Clinical Outcome. / Beck, Stephen D W; Foster, Richard; Bihrle, Richard; Einhorn, Lawrence; Donohue, John P.

In: Urologic Clinics of North America, Vol. 34, No. 2, 05.2007, p. 219-225.

Research output: Contribution to journalArticle

@article{84334091722547a6b1d15e3fef6159b1,
title = "Post Chemotherapy RPLND in Patients with Elevated Markers: Current Concepts and Clinical Outcome",
abstract = "Elevated serum tumor markers after cisplatin-based chemotherapy usually contraindicate surgery because of the presence of active germ-cell elements; however, some patients have undergone PCRPLND with curative intent. We evaluated the role of surgery to resect retroperitoneal-only marker positive tumor. Residual germ-cell cancer was identified in 50{\%} of patients with elevated tumor markers with one third alive at 5 years; 5-year survival with residual teratoma or necrosis was 77.5{\%} and 85.7{\%}, respectively. Predictors of retroperitoneal teratoma or fibrosis included declining tumor makers at surgery, βHCG < 100, and first-line chemotherapy. Predictors of death included rising preoperative βHCG, elevated AFP, redo RPLND, and active germ-cell cancer in the resected specimen. Select patients with elevated tumor markers after chemotherapy are cured with surgery.",
author = "Beck, {Stephen D W} and Richard Foster and Richard Bihrle and Lawrence Einhorn and Donohue, {John P.}",
year = "2007",
month = "5",
doi = "10.1016/j.ucl.2007.02.006",
language = "English",
volume = "34",
pages = "219--225",
journal = "Urologic Clinics of North America",
issn = "0094-0143",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Post Chemotherapy RPLND in Patients with Elevated Markers

T2 - Current Concepts and Clinical Outcome

AU - Beck, Stephen D W

AU - Foster, Richard

AU - Bihrle, Richard

AU - Einhorn, Lawrence

AU - Donohue, John P.

PY - 2007/5

Y1 - 2007/5

N2 - Elevated serum tumor markers after cisplatin-based chemotherapy usually contraindicate surgery because of the presence of active germ-cell elements; however, some patients have undergone PCRPLND with curative intent. We evaluated the role of surgery to resect retroperitoneal-only marker positive tumor. Residual germ-cell cancer was identified in 50% of patients with elevated tumor markers with one third alive at 5 years; 5-year survival with residual teratoma or necrosis was 77.5% and 85.7%, respectively. Predictors of retroperitoneal teratoma or fibrosis included declining tumor makers at surgery, βHCG < 100, and first-line chemotherapy. Predictors of death included rising preoperative βHCG, elevated AFP, redo RPLND, and active germ-cell cancer in the resected specimen. Select patients with elevated tumor markers after chemotherapy are cured with surgery.

AB - Elevated serum tumor markers after cisplatin-based chemotherapy usually contraindicate surgery because of the presence of active germ-cell elements; however, some patients have undergone PCRPLND with curative intent. We evaluated the role of surgery to resect retroperitoneal-only marker positive tumor. Residual germ-cell cancer was identified in 50% of patients with elevated tumor markers with one third alive at 5 years; 5-year survival with residual teratoma or necrosis was 77.5% and 85.7%, respectively. Predictors of retroperitoneal teratoma or fibrosis included declining tumor makers at surgery, βHCG < 100, and first-line chemotherapy. Predictors of death included rising preoperative βHCG, elevated AFP, redo RPLND, and active germ-cell cancer in the resected specimen. Select patients with elevated tumor markers after chemotherapy are cured with surgery.

UR - http://www.scopus.com/inward/record.url?scp=34247615057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247615057&partnerID=8YFLogxK

U2 - 10.1016/j.ucl.2007.02.006

DO - 10.1016/j.ucl.2007.02.006

M3 - Article

VL - 34

SP - 219

EP - 225

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 2

ER -